Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib in early-stage RET fusion-positive NSCLC
NCT04819100Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 32
01
Overview
A Phase 3 trial of selpercatinib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Dec 2021; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04819100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819100.